Yann Joly

List of Publications by Year in descending order

65 papers	1,515 citations	430754 18 h-index	345118 36 g-index
67 all docs	67 docs citations	67 times ranked	2524 citing authors

#	Article	IF	Citations
1	Prepublication data sharing. Nature, 2009, 461, 168-170.	13.7	243
2	Data Sharing in the Post-Genomic World: The Experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO). PLoS Computational Biology, 2012, 8, e1002549.	1.5	100
3	Genetic discrimination and life insurance: a systematic review of the evidence. BMC Medicine, 2013, 11, 25.	2.3	98
4	GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics, 2021, 1, 100029.	3.0	94
5	Epigenetics, ethics, law and society: A multidisciplinary review of descriptive, instrumental, dialectical and reflexive analyses. Social Studies of Science, 2019, 49, 785-810.	1.5	81
6	Comparative Approaches to Genetic Discrimination: Chasing Shadows?. Trends in Genetics, 2017, 33, 299-302.	2.9	63
7	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). Journal of Personalized Medicine, 2021, 11, 511.	1.1	59
8	Ethical issues of CRISPR technology and gene editing through the lens of solidarity. British Medical Bulletin, 2017, 122, 17-29.	2.7	57
9	Genetic discrimination in private insurance: global perspectives. New Genetics and Society, 2010, 29, 351-368.	0.7	51
10	Controlled Access under Review: Improving the Governance of Genomic Data Access. PLoS Biology, 2015, 13, e1002339.	2.6	42
11	Life insurance: genomic stratification and risk classification. European Journal of Human Genetics, 2014, 22, 575-579.	1.4	41
12	Harm, hype and evidence: ELSI research and policy guidance. Genome Medicine, 2013, 5, 21.	3.6	39
13	Looking Beyond GINA: Policy Approaches to Address Genetic Discrimination. Annual Review of Genomics and Human Genetics, 2020, 21, 491-507.	2.5	38
14	Epigenome data release: a participant-centered approach to privacy protection. Genome Biology, 2015, 16, 142.	3.8	34
15	Epigenetic Discrimination: Emerging Applications of Epigenetics Pointing to the Limitations of Policies Against Genetic Discrimination. Frontiers in Genetics, 2018, 9, 202.	1.1	29
16	Points-to-consider on the return of results in epigenetic research. Genome Medicine, 2019, 11, 31.	3.6	27
17	Genomic databases access agreements: legal validity and possible sanctions. Human Genetics, 2011, 130, 441-449.	1.8	24
18	International federation of genomic medicine databases using GA4GH standards. Cell Genomics, 2021, 1, 100032.	3.0	22

#	Article	IF	Citations
19	Physicians, genetics and life insurance. Cmaj, 2004, 170, 1421-1423.	0.9	19
20	Benefits and barriers in the design of harmonized access agreements for international data sharing. Scientific Data, 2019, 6, 297.	2.4	18
21	Establishing the International Genetic Discrimination Observatory. Nature Genetics, 2020, 52, 466-468.	9.4	18
22	Genetics and Personal Insurance: the Perspectives of Canadian Cancer Genetic Counselors. Journal of Genetic Counseling, 2015, 24, 1022-1036.	0.9	17
23	Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. Frontiers in Genetics, 2017, 8, 128.	1.1	17
24	Genetic discrimination: introducing the Asian perspective to the debate. Npj Genomic Medicine, 2021, 6, 54.	1.7	16
25	Risk of re-identification of epigenetic methylation data: a more nuanced response is needed. Clinical Epigenetics, 2015, 7, 45.	1.8	14
26	Disease Resistance and the Definition of Genetic Enhancement. Frontiers in Genetics, 2017, 8, 40.	1.1	13
27	South Korea: in the midst of a privacy reform centered on data sharing. Human Genetics, 2018, 137, 627-635.	1.8	13
28	Introduction: the why and whither of genomic data sharing. Human Genetics, 2018, 137, 569-574.	1.8	13
29	Genomics for All: International Open Science Genomics Projects and Capacity Building in the Developing World. Frontiers in Genetics, 2019, 10, 95.	1.1	13
30	Evolving data access policy: The Canadian context. Facets, 2017, 1, 138-147.	1.1	13
31	Falling giants and the rise of gene editing: ethics, private interests and the public good. Human Genomics, 2017, 11, 20.	1.4	12
32	Issues related to family history of cancer at the end of life: a palliative care providersâ€™ survey. Familial Cancer, 2018, 17, 303-307.	0.9	12
33	Open science and community norms. Medical Law International, 2012, 12, 92-120.	0.4	10
34	CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis. Cell Genomics, 2021, 1, 100033.	3.0	10
35	Harnessing Omics Sciences, Population Databases, and Open Innovation Models for Theranosticsâ€Guided Drug Discovery and Development. Drug Development Research, 2012, 73, 439-446.	1.4	9
36	Social, ethical and legal considerations raised by the discovery and patenting of the BRCA1 and BRCA2 genes. New Genetics and Society, 2014, 33, 167-180.	0.7	9

#	Article	IF	Citations
37	DNA Testing for Family Reunification in Canada: Points to Consider. Journal of International Migration and Integration, 2017, 18, 391-404.	0.8	9
38	Modeling consent in the time of COVID-19. Journal of Law and the Biosciences, 2020, 7, lsaa020.	0.8	9
39	Selling direct-to-consumer epigenetic tests: are we ready?. Nature Reviews Genetics, 2020, 21, 335-336.	7.7	9
40	Human rights in the postgenomic era: Challenges and opportunities arising with epigenetics. Social Science Information, 2020, 59, 12-34.	1.1	8
41	Is it research or is it clinical? Revisiting an old frontier through the lens of next-generation sequencing technologies. European Journal of Medical Genetics, 2018, 61, 634-641.	0.7	7
42	The omics of our lives: practices and policies of direct-to-consumer epigenetic and microbiomic testing companies. New Genetics and Society, 2021, 40, 541-569.	0.7	7
43	A step forward, but still inadequate: Australian health professionalsâ€™ views on the genetics and life insurance moratorium. Journal of Medical Genetics, 2022, 59, 817-826.	1.5	6
44	Engaged genomic science produces better and fairer outcomes: an engagement framework for engaging and involving participants, patients and publics in genomics research and healthcare implementation. Wellcome Open Research, 2021, 6, 311.	0.9	6
45	Addressing cancer family history at the end of life: How frequent, relevant, and feasible is it? A survey of palliative care providers. Palliative Medicine, 2019, 33, 856-858.	1.3	5
46	Risk-Stratified Approach to Breast Cancer Screening in Canada: Womenâ€™s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. Journal of Personalized Medicine, 2021, 11, 726.	1.1	5
47	Regulatory approval for new pharmacogenomic tests: a comparative overview. Food and Drug Law Journal, 2011, 66, 1-24, i.	0.4	5
48	Addressing Privacy Concerns in Sharing Viral Sequences and Minimum Contextual Data in a Public Repository During the COVID-19 Pandemic. Frontiers in Genetics, 2021, 12, 716541.	1.1	5
49	Disclosure of insurability risks in research and clinical consent forms. Global Bioethics, 2016, 27, 38-49.	0.5	4
50	Communication of genetic information in the palliative care context: Ethical and legal issues. Medical Law International, 2018, 18, 219-240.	0.4	4
51	Country Reports. Journal of Law, Medicine and Ethics, 2019, 47, 582-704.	0.4	4
52	What do cancer patientsâ€™ relatives think about addressing cancer family history and performing genetic testing in palliative care?. European Journal of Human Genetics, 2020, 28, 213-221.	1.4	4
53	Communicating science: epigenetics in the spotlight. Environmental Epigenetics, 2020, 6, dvaa015.	0.9	4
54	The commercialization of genomic research in Canada. Healthcare Policy, 2010, 6, 24-32.	0.3	4

#	Article	IF	Citations
55	Diagnostic Testing for Vaccinomics: Is the Regulatory Approval Framework Adequate? A Comparison of Canada, the United States, and Europe. OMICS A Journal of Integrative Biology, 2011, 15, 597-605.	1.0	3
56	Currents in Contemporary Bioethics: Open Access as Benefit Sharing? The Example of Publicly Funded Large-Scale Genomic Databases. Journal of Law, Medicine and Ethics, 2012, 40, 143-146.	0.4	3
57	Assessing public opinions on the likelihood and permissibility of gene editing through construal level theory. New Genetics and Society, 2021, 40, 473-497.	0.7	3
58	Anti-Selection & Genetic Testing in Insurance: An Interdisciplinary Perspective. Journal of Law, Medicine and Ethics, 2022, 50, 139-154.	0.4	3
59	Clinical exome sequencing in France and Quebec: what are the challenges? What does the future hold?. Life Sciences, Society and Policy, 2018, 14, 17.	3.1	2
60	Overcoming Biases Together: Normative Stakes of Interdisciplinarity in Bioethics. AJOB Empirical Bioethics, 2020, 11, 20-23.	0.8	2
61	Survey of palliative care providersâ€™ needs, perceived roles, and ethical concerns about addressing cancer family history at the end of life. Palliative and Supportive Care, 2021, 19, 217-222.	0.6	2
62	Genetic discrimination views in online discussion forums: Perspectives from Canadian forumites. Journal of Genetic Counseling, 2021, 30, 1613-1628.	0.9	2
63	A decision tool to guide the ethics review of a challenging breed of emerging genomic projects. European Journal of Human Genetics, 2016, 24, 1099-1103.	1.4	0
64	Anti-selection & Genetic Testing in Insurance: An Interdisciplinary Perspective. SSRN Electronic Journal, 0, , .	0.4	0
65	Genetic Discrimination in Access to Life Insurance: Does Ukrainian Legislation Offer Sufficient Protection against the Adverse Consequences of the Genetic Revolution to Insurance Applicants?. Laws, 2022, 11, 2.	0.5	0